Skip to main content

Illinois State Court Judge Issues Contempt Order Against J&J

Illinois State Court Judge Issues Contempt Order Against J&J

Illinois State Court Judge Issues Contempt Order Against J&J

Introduction

Illinois judge held Johnson & Johnson (J&J) in contempt on July 26, Monday, as one of the company's executives refused to reappear before the court to testify in the ongoing talcum powder trial.

According to the court documents, the plaintiff alleged that his sister died in 2016 from ovarian cancer caused by talc exposure.

Earlier, J&J's executive appeared before the court to testify in the trial but refused to reappear for cross-examination. Attorneys for J&J claim that the company informed the court beforehand that the executive will not be able to attend the court in person and will be available via video-conference. The state court judge rejected the company's request of arranging a video conference trial and announced that the company and the executive were in contempt of the court.

The trial will not have any impact on the other pending Baby Powder lawsuits and Shower-to-Shower lawsuits from women across the country. All the lawsuits claim similar allegations that the talc products of J&J caused ovarian cancer to the women.

The company is already being hit with several billion in damages in the lawsuits after the evaluation of evidence by the juries.

J&J will face the first federal talcum powder trial in April 2022. U.S. District Judge Freda L. Wolfson is overseeing all the talcum powder lawsuits in the District of New Jersey, where all the lawsuits are consolidated under an MDL.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!